Iovance [IOVA] vs Beam Therapeutics [BEAM] Detailed Stock Comparison
Iovance
NASDAQ
Loading...
Beam Therapeutics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Iovance wins in 9 metrics, Beam Therapeutics wins in 8 metrics, with 0 ties. Iovance appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Iovance | Beam Therapeutics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -1.64 | -3.85 | Beam Therapeutics |
| Price-to-Book Ratio | 1.12 | 1.59 | Iovance |
| Debt-to-Equity Ratio | 7.00 | 14.08 | Iovance |
| PEG Ratio | -3.15 | -3.84 | Beam Therapeutics |
| EV/EBITDA | -1.52 | -1.70 | Beam Therapeutics |
| Profit Margin (TTM) | -176.49% | 0.00% | Beam Therapeutics |
| Operating Margin (TTM) | -245.77% | -1,419.22% | Iovance |
| Return on Equity | -51.85% | -51.36% | Beam Therapeutics |
| Return on Assets (TTM) | -27.14% | -34.13% | Iovance |
| Free Cash Flow (TTM) | $-364.05M | $-356.19M | Beam Therapeutics |
| 1-Year Return | -78.73% | -28.00% | Beam Therapeutics |
| Price-to-Sales Ratio (TTM) | 4.05 | 30.72 | Iovance |
| Enterprise Value | $555.56M | $722.17M | Beam Therapeutics |
| EV/Revenue Ratio | 2.61 | 11.98 | Iovance |
| Gross Profit Margin (TTM) | -0.85% | N/A | N/A |
| Revenue per Share (TTM) | $1 | $1 | Iovance |
| Earnings per Share (Diluted) | $-1.22 | $-4.50 | Iovance |
| Beta (Stock Volatility) | 0.88 | 2.23 | Iovance |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Iovance vs Beam Therapeutics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Iovance | -20.08% | -21.27% | 19.21% | -33.44% | -60.34% | -72.91% |
| Beam Therapeutics | -1.34% | -6.43% | -13.20% | 2.14% | -33.68% | -28.66% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Iovance | -78.73% | -83.33% | -92.41% | -70.49% | -98.08% | -98.08% |
| Beam Therapeutics | -28.00% | -74.51% | -21.66% | -14.60% | -14.60% | -14.60% |
Performance & Financial Health Analysis: Iovance vs Beam Therapeutics
| Metric | IOVA | BEAM |
|---|---|---|
| Market Information | ||
| Market Cap | $861.55M | $1.85B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 18,797,860 | 2,377,750 |
| 90 Day Avg. Volume | 20,690,350 | 2,456,103 |
| Last Close | $2.11 | $17.62 |
| 52 Week Range | $1.64 - $12.51 | $13.52 - $35.25 |
| % from 52W High | -83.13% | -50.01% |
| All-Time High | $165.00 (Jun 06, 2011) | $138.52 (Jun 28, 2021) |
| % from All-Time High | -98.72% | -87.28% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 67.99% | -0.28% |
| Quarterly Earnings Growth | 67.98% | -0.28% |
| Financial Health | ||
| Profit Margin (TTM) | -1.76% | 0.00% |
| Operating Margin (TTM) | -2.46% | -14.19% |
| Return on Equity (TTM) | -0.52% | -0.51% |
| Debt to Equity (MRQ) | 7.00 | 14.08 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $2.30 | $11.52 |
| Cash per Share (MRQ) | $1.08 | $12.51 |
| Operating Cash Flow (TTM) | $-334,392,000 | $-273,268,000 |
| Levered Free Cash Flow (TTM) | $-184,756,624 | $-376,742,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Iovance vs Beam Therapeutics
| Metric | IOVA | BEAM |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -1.64 | -3.85 |
| Forward P/E | -3.15 | -3.84 |
| PEG Ratio | -3.15 | -3.84 |
| Price to Sales (TTM) | 4.05 | 30.72 |
| Price to Book (MRQ) | 1.12 | 1.59 |
| Market Capitalization | ||
| Market Capitalization | $861.55M | $1.85B |
| Enterprise Value | $555.56M | $722.17M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.61 | 11.98 |
| Enterprise to EBITDA | -1.52 | -1.70 |
| Risk & Other Metrics | ||
| Beta | 0.88 | 2.23 |
| Book Value per Share (MRQ) | $2.30 | $11.52 |
Financial Statements Comparison: Iovance vs Beam Therapeutics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IOVA | BEAM |
|---|---|---|
| Revenue/Sales | $49.32M | $7.47M |
| Cost of Goods Sold | $49.74M | N/A |
| Gross Profit | $-417,000 | N/A |
| Research & Development | $76.88M | $98.82M |
| Operating Income (EBIT) | $-121.22M | $-119.29M |
| EBITDA | $-110.16M | $-113.91M |
| Pre-Tax Income | $-118.00M | $-109.27M |
| Income Tax | $-1.84M | N/A |
| Net Income (Profit) | $-116.16M | $-109.27M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IOVA | BEAM |
|---|---|---|
| Cash & Equivalents | $171.67M | $527.91M |
| Total Current Assets | $512.65M | $1.25B |
| Total Current Liabilities | $122.69M | $141.55M |
| Long-Term Debt | $44.22M | $144.92M |
| Total Shareholders Equity | $767.87M | $1.12B |
| Retained Earnings | $-2.50B | $-1.68B |
| Property, Plant & Equipment | $82.32M | $176.23M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IOVA | BEAM |
|---|---|---|
| Operating Cash Flow | $-100.65M | $-81.45M |
| Capital Expenditures | $-6.21M | $-3.07M |
| Free Cash Flow | $-109.91M | $-106.95M |
| Debt Repayment | N/A | $0 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | IOVA | BEAM |
|---|---|---|
| Shares Short | 98.63M | 23.66M |
| Short Ratio | 8.04 | 9.87 |
| Short % of Float | 0.32% | 0.26% |
| Average Daily Volume (10 Day) | 18,797,860 | 2,377,750 |
| Average Daily Volume (90 Day) | 20,690,350 | 2,456,103 |
| Shares Outstanding | 305.25M | 83.63M |
| Float Shares | 280.26M | 86.27M |
| % Held by Insiders | 0.00% | 0.01% |
| % Held by Institutions | 0.81% | 0.99% |
Dividend Analysis & Yield Comparison: Iovance vs Beam Therapeutics
| Metric | IOVA | BEAM |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |